Capital Advantage Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 9.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,042 shares of the company’s stock after selling 889 shares during the period. Johnson & Johnson accounts for 0.3% of Capital Advantage Inc.’s portfolio, making the stock its 26th largest position. Capital Advantage Inc.’s holdings in Johnson & Johnson were worth $1,159,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. Enterprise Financial Services Corp raised its stake in Johnson & Johnson by 2.4% in the fourth quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock worth $2,106,000 after buying an additional 358 shares in the last quarter. Welch Investments LLC raised its stake in Johnson & Johnson by 1.0% in the fourth quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock worth $5,027,000 after buying an additional 373 shares in the last quarter. YHB Investment Advisors Inc. raised its stake in Johnson & Johnson by 0.5% in the fourth quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock worth $10,693,000 after buying an additional 381 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC raised its stake in Johnson & Johnson by 1.0% in the fourth quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock worth $5,363,000 after buying an additional 382 shares in the last quarter. Finally, Regent Investment Management LLC raised its stake in Johnson & Johnson by 0.8% in the fourth quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock worth $6,591,000 after buying an additional 385 shares in the last quarter. 65.96% of the stock is owned by institutional investors.

NYSE:JNJ opened at $122.57 on Wednesday. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58. The company has a market cap of $328.95 billion, a PE ratio of 16.79, a PEG ratio of 1.88 and a beta of 0.73.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The firm had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. During the same quarter in the prior year, the company posted $1.83 earnings per share. The business’s revenue for the quarter was up 12.6% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th were issued a dividend of $0.90 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend was Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.94%. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

A number of equities analysts recently issued reports on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price target for the company in a research note on Thursday, April 5th. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price target for the company. in a research note on Monday, March 26th. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 10th. Six research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $142.23.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.